# Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation

> **NCT03589014** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 71 (actual)

## Conditions studied

- Cerebral Cavernous Malformation

## Interventions

- **DRUG:** Propranolol

## Key facts

- **NCT ID:** NCT03589014
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-11
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2022-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589014, "Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03589014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*